Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant’s report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.
Continue reading Pfizer’s Potential Arthritis Drug Works in Late-Stage Trial
Pfizer’s Potential Arthritis Drug Works in Late-Stage Trial originally appeared on DailyFinance on Mon, 08 Nov 2010 15:42:00.
Filed Under: Company News, Health Care, Pfizer